Description
Mechanism of Action
Mefenamic acid, an anthranilic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It has analgesic and antipyretic properties w/ minor anti-inflammatory activity.
Duration: ≤6 hr.
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: Approx 2-4 hr.
Distribution: Enters breast milk (small amounts). Volume of distribution: 1.06 L/kg. Plasma protein binding: >90%.
Metabolism: Metabolised by CYP2C9 isoenzyme to 3-hydroxymethyl mefenamic acid, which may then be oxidised to 3-carboxymefenamic acid.
Excretion: Via urine (approx 52%) as unchanged drug and metabolites; faeces (approx 20%). Elimination half-life: Approx 2-4 hr.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AG01 – mefenamic acid; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.;
